Do Mpox virus proteins undergo post-translational modifications, and should PTMs be considered in in-silico vaccine/antibody design?

I'm working on an in-silico study involving the Mpox virus, and I have a question regarding post-translational modifications (PTMs).

Specifically, do the Mpox virus proteins A35R (EEV protein) and H3L and M1R (IMV proteins) undergo post-translational modifications? If they do, are these modifications carried out by the host cell machinery, by virus-encoded enzymes, or by a combination of both?

My second question is related to immunoinformatics. If an in silico vaccine or antibody is being designed against these proteins, should their PTMs be evaluated before selecting epitopes or designing antibodies? In other words, could PTMs significantly affect epitope accessibility, antigenicity, antibody binding, or the overall reliability of computational predictions?

I'd appreciate any insights or relevant literature.

Thanks!